Addyi and Pregabalin Interaction: What Every Woman Needs to Know

What the Addyi-Pregabalin Interaction Actually Is

The combination of flibanserin and pregabalin creates an additive central nervous system (CNS) depression problem. Neither drug is a classic sedative, yet both reduce neural excitability through distinct mechanisms, and those effects stack.

Flibanserin works in the brain as a serotonin 1A agonist and serotonin 2A antagonist, with additional dopamine D4 agonist activity. Its net effect in the prefrontal cortex shifts the balance between inhibitory serotonergic tone and excitatory dopaminergic/norepinephrine tone, which is how it is thought to increase sexual desire, but that same activity produces sedation as a dose-dependent side effect. Pregabalin binds to the alpha-2-delta subunit of voltage-gated calcium channels throughout the CNS, reducing calcium influx and dampening neuronal excitability. In randomized controlled trials of pregabalin, somnolence occurred in 18-28% of patients and dizziness in 22-35%, dose-dependently.

When you layer those two mechanisms together, you do not get simple arithmetic addition. CNS sedation pathways converge, and the clinical result can be disproportionate.

The FDA's Position on Addyi and CNS Depressants

The FDA-approved prescribing information for flibanserin carries a Boxed Warning stating that concomitant use with alcohol or CNS depressants increases the risk of hypotension, syncope, and CNS depression. The label does not single out pregabalin by name, but pregabalin fits squarely within the CNS depressant class by mechanism and by the clinical sedation and dizziness data from its own trials.

The label instructs prescribers to assess all concomitant CNS-depressant use before starting flibanserin and to counsel women to avoid alcohol and to use caution with any agent that depresses the CNS.

Pharmacokinetic Considerations

Pharmacokinetic (PK) drug interactions involve one drug changing how the body absorbs, distributes, metabolizes, or excretes another. With this specific combination, the PK story is relatively reassuring but not clean.

Flibanserin is metabolized primarily by CYP3A4 and, to a lesser extent, CYP2C19. Pregabalin is not appreciably metabolized by cytochrome P450 enzymes at all. Pregabalin is excreted largely unchanged in urine, with renal clearance accounting for nearly 90% of its elimination. That means pregabalin does not increase flibanserin plasma levels through enzyme inhibition, and flibanserin does not meaningfully alter pregabalin exposure.

The interaction is almost entirely pharmacodynamic (PD): two drugs producing overlapping CNS effects simultaneously.

There is one caveat. Flibanserin's exposure increases substantially with CYP3A4 inhibitors (fluconazole, for example, raises flibanserin AUC by roughly 7-fold). If a woman taking both flibanserin and pregabalin also takes a CYP3A4 inhibitor for another condition, the combined sedation risk becomes considerably greater because flibanserin levels themselves rise.

How Serious Is This Interaction in Practice?

Clinicians use several frameworks to classify drug-drug interaction (DDI) severity. Across major DDI databases (Lexicomp, Micromedex, Clinical Pharmacology), the flibanserin-pregabalin pair is generally classified as moderate, meaning the combination is not absolutely contraindicated but warrants active clinical judgment, dose review, and patient counseling before co-prescribing.

A "moderate" classification in DDI databases does not mean "safe without thought." It means the risk is real but manageable with appropriate precautions, and that for some women the benefit of both drugs may justify that managed risk.

Factors That Raise the Risk in Women

Women face a set of physiological factors that amplify sedation and hypotension risk from CNS-active drugs:

• Lower body weight and volume of distribution. Flibanserin's recommended dose is 100 mg at bedtime regardless of weight. Women with lower body mass reach relatively higher peak concentrations per kilogram.
• Hormonal variation across the cycle. Progesterone, which rises in the luteal phase, is itself a neurosteroid with GABAergic sedating properties. Combining pregabalin with flibanserin in the high-progesterone luteal phase may produce greater CNS depression than during the follicular phase, though this specific interaction has not been studied in a controlled trial. The evidence here is extrapolated from progesterone's known CNS pharmacology.
• Perimenopause and sleep disruption. Women in perimenopause often have fragmented sleep. Pregabalin is sometimes prescribed off-label for vasomotor symptoms and sleep in this group. If a perimenopausal woman is also using flibanserin (noting that flibanserin is currently approved only for premenopausal women), the sedation layering becomes clinically meaningful. The Menopause Society's 2023 position statement on hormone therapy does not address flibanserin-pregabalin combinations directly, but flags CNS-active agents as requiring individualized review in this age group.
• Fall risk. Dizziness is among the most common reasons older premenopausal and perimenopausal women sustain injuries. Adding sedation and blood-pressure lowering from two drugs simultaneously increases fall and injury risk in the hours after dosing.

Factors That May Lower the Risk

• Low pregabalin doses (e.g., 75 mg at bedtime for neuropathic pain) produce less sedation than doses used for fibromyalgia (300-450 mg/day) or generalized anxiety disorder.
• Stable, long-term pregabalin use with known individual tolerability is a better baseline than a new or recently titrated prescription.
• Women who are not consuming alcohol, not taking additional CNS depressants, and have no cardiovascular instability present a lower absolute risk profile.

Life-Stage Guide: Who Is Most Affected

Reproductive Years (Ages 18-40), Trying to Conceive

Flibanserin is approved specifically for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). This is the core approved population. Women in this group who also take pregabalin for epilepsy, generalized anxiety disorder, fibromyalgia, or neuropathic pain need explicit counseling on the additive sedation and on contraception (see Pregnancy section below).

Perimenopause

Flibanserin carries no FDA approval for perimenopausal women. A 2016 post-marketing study, RECONNECT, evaluated bremelanotide rather than flibanserin in menopause-age women, illustrating how limited the data are for older reproductive-age women. Prescribers who use flibanserin off-label in perimenopause are doing so outside the approved indication, and adding pregabalin to that regimen compounds an already evidence-thin scenario.

Postmenopause

No evidence supports flibanserin efficacy in postmenopausal women. The FDA label does not include this population. If a postmenopausal woman asks about this combination, the starting answer is that flibanserin is not indicated for her.

Pregnancy and Lactation: Required Reading

Flibanserin is contraindicated during pregnancy. Stop flibanserin before attempting conception and use reliable contraception throughout treatment.

Flibanserin in Pregnancy

Flibanserin's prescribing label notes that animal reproductive studies showed embryo-fetal toxicity at exposures below the human therapeutic dose, including increased post-implantation loss. There are no adequate and well-controlled studies in pregnant women. Based on animal data and the drug's CNS mechanism, use in pregnancy cannot be considered safe. Women who become pregnant while taking flibanserin should stop the drug immediately and contact their clinician.

Pregabalin in Pregnancy

Pregabalin is more complex. A 2019 NEJM study by Winterfeld et al. Found a major malformation rate of 6.0% in pregabalin-exposed pregnancies compared with 2.1% in controls, though methodological limitations prevent firm conclusions. The European Medicines Agency in 2019 updated pregabalin's label to warn of potential fetal harm and recommended effective contraception for women of childbearing potential taking pregabalin. The FDA label for pregabalin carries a Pregnancy Category C designation, meaning animal studies have shown adverse effects and human data are insufficient.

If you are taking pregabalin for a condition where stopping is medically unsafe (for example, epilepsy), a conversation with your neurologist and OB before any pregnancy attempt is not optional.

Lactation

Flibanserin transfer into human breast milk has not been studied. Given that animal data show flibanserin is distributed into rat milk, and given the drug's CNS activity, breastfeeding while taking flibanserin is not advised. The drug has no approved indication for postpartum women, and postpartum HSDD has distinct hormonal drivers (primarily low estrogen and elevated prolactin) that flibanserin does not address.

Pregabalin does transfer into breast milk. A pharmacokinetic study found infant exposure to pregabalin via breast milk was approximately 7% of the maternal weight-adjusted dose, which is generally below the threshold of concern but warrants monitoring for infant sedation if nursing continues during maternal pregabalin use.

Who This Combination Is Right For, and Who It Is Not

Potentially Manageable With Supervision

• A premenopausal woman with confirmed HSDD who has been stable on low-dose pregabalin (75 mg nightly) for neuropathic pain, does not consume alcohol, does not take other CNS depressants, has no history of syncope, and whose prescribers communicate directly about the co-prescription.
• A woman whose HSDD is significantly affecting her quality of life and relationship, for whom non-pharmacologic interventions (sex therapy, couples therapy, mindfulness-based interventions) have been tried and found insufficient.

Not Appropriate

• Any woman who consumes alcohol regularly. The FDA Boxed Warning on flibanserin for alcohol interaction is explicit: even moderate alcohol use within hours of flibanserin dosing can cause dangerous hypotension.
• Women taking opioids, benzodiazepines, antihistamines, or other CNS depressants in addition to pregabalin. The sedation stack becomes clinically unmanageable.
• Women with a history of syncope, orthostatic hypotension, or cardiovascular instability.
• Women who are pregnant, planning pregnancy within the treatment period, or breastfeeding.
• Perimenopausal or postmenopausal women (flibanserin is not approved for this group).
• Women with significant hepatic impairment. Flibanserin is contraindicated in hepatic impairment because CYP3A4 metabolism is reduced, raising plasma levels substantially.

Monitoring and Clinical Management

Before Co-Prescribing

1. Confirm HSDD diagnosis using validated tools. The Female Sexual Function Index (FSFI) and the Decreased Sexual Desire Screener (DSDS) are standard instruments.
2. Review the complete medication list. Flag every CNS-active drug, including over-the-counter antihistamines and sleep aids.
3. Assess alcohol use with a validated tool (AUDIT-C). Flibanserin's Boxed Warning and the REMS program (see below) center on alcohol prohibition.
4. Measure baseline blood pressure and document fall risk.
5. Confirm contraception status and HSDD life-stage appropriateness.

The Addyi REMS Program

Because of its interaction risk profile, flibanserin is available only through a Risk Evaluation and Mitigation Strategy (REMS) program called ADDYI REMS. Both the prescriber and the pharmacy must be certified. Patients receive a Medication Guide. This is not bureaucratic box-checking. It means every flibanserin prescription involves a formal acknowledgment that the prescriber has counseled the patient about alcohol and CNS depressant risks.

Ongoing Monitoring

• Re-evaluate sedation level and functional status after the first four weeks on the combination.
• Ask specifically about morning-after impairment. Flibanserin is taken at bedtime, and residual sedation the next morning has been reported. In the SUNFLOWER trial, somnolence was the most common adverse event, occurring in 11.4% of flibanserin-treated women versus 4.0% of placebo.
• If pregabalin is being titrated upward for pain or anxiety, re-evaluate the flibanserin combination at each dose step.
• Discontinue flibanserin if there is no improvement in HSDD after eight weeks of consistent 100 mg nightly dosing. Continuing the exposure risk beyond a reasonable therapeutic window is not justified.

Dose Adjustment

There is no approved dose reduction for flibanserin. The approved dose is 100 mg at bedtime. Reducing flibanserin dose to manage the interaction is off-label and unlikely to preserve efficacy.

Pregabalin dose reduction may be possible depending on the underlying indication and the prescribing specialist's clinical judgment. This is a conversation between you, your clinician prescribing pregabalin, and your clinician managing HSDD.

Evidence Gaps: What We Do Not Know

Women have been historically underrepresented in CNS pharmacology trials. The specific flibanserin-pregabalin combination has not been studied in a dedicated interaction trial. The risk assessment above is built from:

• Flibanserin's own phase 3 trial data on CNS adverse events (SUNFLOWER, VIOLET, DAISY trials).
• Pregabalin's regulatory pharmacokinetic data showing no CYP450 involvement.
• Class-level evidence on additive CNS depression from CNS depressant combinations.
• Extrapolation from the flibanserin-alcohol interaction, which is the most studied of flibanserin's interactions.

The female-specific pharmacodynamic data, including how menstrual cycle phase, exogenous hormones (combined oral contraceptives, progestogen implants), or perimenopausal hormonal flux alter this specific combination, do not exist in the published literature. That is a meaningful gap. Clinicians and patients are making decisions in the absence of cycle-specific or hormone-status-specific PK data.

Alternative Approaches for HSDD When Pregabalin Co-Use Is a Concern

If the combination carries too much risk for your specific situation, these options exist:

• Bremelanotide (Vyleesi): A melanocortin receptor agonist administered as a subcutaneous injection before anticipated sexual activity. It carries no CNS depressant Boxed Warning and its interaction profile with pregabalin is distinct from flibanserin's, though nausea and transient blood pressure changes are common. Approved for premenopausal women with HSDD.
• Psychosexual therapy: Mindfulness-based cognitive therapy for sexual dysfunction showed statistically significant improvement in sexual desire in a randomized trial by Brotto et al. Non-pharmacologic approaches avoid the drug interaction problem entirely.
• Treating the underlying driver: In perimenopausal women with low desire, low estrogen and testosterone are often the primary drivers. Testosterone therapy, though not FDA-approved for women, has a meaningful evidence base summarized in the 2019 Global Consensus Position Statement, and does not carry a CNS depressant interaction with pregabalin.
• Addressing pregabalin's own effect on libido: Pregabalin itself may suppress sexual desire as a CNS-mediated side effect. If pregabalin is the primary contributor to reduced desire, discussing alternative analgesics or anxiolytics with the prescribing specialist may resolve the HSDD without adding flibanserin at all.

Practical Counseling Points for Your Appointment

Bring this list to your prescriber visit:

1. A complete medication list including OTC drugs, supplements, and alcohol use frequency.
2. Ask: "Is my pregabalin dose and indication one where the CNS sedation risk with flibanserin is acceptable?"
3. Ask: "Have my flibanserin prescriber and my pregabalin prescriber communicated directly about this combination?"
4. Confirm you are enrolled in the ADDYI REMS program if flibanserin is prescribed.
5. Arrange for someone to be available to help you the first few nights on both drugs, in case sedation or hypotension is severe.
6. Set a calendar reminder for a four-week check-in call to report any morning sedation, dizziness, or falls.

If you experience severe dizziness, fainting, or difficulty staying awake in the morning, stop flibanserin and contact your clinician the same day.